A message from Diurnal – Chronocort Development Programme

Nov 21, 2019

A message from Diurnal:

CH EU-EU-0060 Date of preparation October 2019

Update for patient groups on Chronocort development programme and timetable

In response to questions we have received from patients, we would like to provide a short update about the plans and timelines for Chronocort marketing in Europe.

Chronocort has been designed to mimic the circadian rhythm of cortisol when given twice daily (last thing at night before sleep and first thing in the morning on waking).

After successful Phase I and II studies, Chronocort did not meet the primary endpoint in its European Phase III trial for the treatment of congenital adrenal hyperplasia (CAH). Diurnal performed further post-hoc analysis of the clinical trial data revealing important differences between Chronocort and the control arm. Formal Scientific Advice from the European Medicines Agency (EMA) confirmed the clinical and regulatory path for Chronocort as a treatment for adult and adolescent patients with CAH.

Thus, Diurnal intends to submit the Marketing Authorisation Application (MAA) in Q4 2019 based on the existing clinical trial data and would anticipate approval in early 2021.

Following a successful marketing authorisation application, Diurnal then intends to file an extension of the Chronocort marketing authorisation for adrenal insufficiency.

Recent Blog Posts

What you should know about COVID-19 – updated 10th August 2021

What you should know about COVID-19 – updated 10th August 2021

Guidance from other organizations is continually being issued and we'll do our best to link to them below - please keep checking back here for more updates. UPDATE 10th August 2021 Article: “ChAdOx1 SARS‐CoV‐2 vaccination: A putative precipitant of adrenal crises”...

New Drug Research Study (LuAG13909): Participants wanted

New Drug Research Study (LuAG13909): Participants wanted

 The study, run by Guy's and St Thomas' NHS Foundation Trust, London UK, will evaluate the effects of different doses of the study drug, Lu AG13909 in adult participants with congenital adrenal hyperplasia (CAH). Individuals with CAH have abnormally low levels of...

Research – Emotion Perception in Youth with CAH

Research – Emotion Perception in Youth with CAH

"Altered Emotion Perception Linked to Structural Brain Differences in Youth With Congenital Adrenal Hyperplasia" From Volume 25, Fall 2023 Cares Foundataion Newsletter "Conclusion: Findings suggest that youth with CAH perceive emotive stimuli as more unpleasant....

Annual General Meeting – 26th November, 10:30am UK time via MS Teams

Annual General Meeting – 26th November, 10:30am UK time via MS Teams

The CAH Support Group is pleased to announce its 5th Annual General Meeting (AGM). It will be held virtually, via MS Teams, on 26th November 2023 at 10:30 am UK time. If you'd like to see the agenda and/or attend, please contact Sallyann (her details are on the ‘Meet...

The CAH Support Group is affiliated with Society for Endocrinology, an organisation that supports clinicians, scientists and nurses who work with hormones throughout their careers. They engage policy-makers, journalists, patients and the public with hormone science to encourage informed health decisions, and to demonstrate the value of endocrinology to the wider world and also maintains a public information website, You and Your Hormones.

All content on this website (livingwithcah.com) is copyright the CAH Support Group unless otherwise stated.

The CAH Support Group cannot be held responsible for the content provided by any external links unless stated.

Cookie Policy | Privacy Policy | Disclaimer | Forum & Social Media Rules | Contact Us